2025 Q3 -tulosraportti
21 päivää sittenTarjoustasot
Xetra
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,12VWAP
Alin
3,01VaihtoMäärä
0 7 691
VWAP
Ylin
3,12Alin
3,01VaihtoMäärä
0 7 691
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.11. | |
| 2025 Q2 -tulosraportti | 17.7. | |
| 2024 Q3 -tulosraportti | 7.11.2024 | |
| 2023 Q4 -tulosraportti | 15.5.2024 | |
| 2023 Q3 -tulosraportti | 20.11.2023 |
Datan lähde: FactSet
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 päivää sittenUS stocks are soaring on this news right now. https://www.cnbc.com/2025/12/12/cannabis-stocks-trump-regulations.html I wonder if there will be a delayed effect in Europe on Monday? FOMO?- ·3 päivää sittenHas anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
21 päivää sittenUutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenUS stocks are soaring on this news right now. https://www.cnbc.com/2025/12/12/cannabis-stocks-trump-regulations.html I wonder if there will be a delayed effect in Europe on Monday? FOMO?
- ·3 päivää sittenHas anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,12VWAP
Alin
3,01VaihtoMäärä
0 7 691
VWAP
Ylin
3,12Alin
3,01VaihtoMäärä
0 7 691
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.11. | |
| 2025 Q2 -tulosraportti | 17.7. | |
| 2024 Q3 -tulosraportti | 7.11.2024 | |
| 2023 Q4 -tulosraportti | 15.5.2024 | |
| 2023 Q3 -tulosraportti | 20.11.2023 |
Datan lähde: FactSet
2025 Q3 -tulosraportti
21 päivää sittenUutiset ja analyysit
Ei uutisia tällä hetkellä
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 24.11. | |
| 2025 Q2 -tulosraportti | 17.7. | |
| 2024 Q3 -tulosraportti | 7.11.2024 | |
| 2023 Q4 -tulosraportti | 15.5.2024 | |
| 2023 Q3 -tulosraportti | 20.11.2023 |
Datan lähde: FactSet
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 päivää sittenUS stocks are soaring on this news right now. https://www.cnbc.com/2025/12/12/cannabis-stocks-trump-regulations.html I wonder if there will be a delayed effect in Europe on Monday? FOMO?
- ·3 päivää sittenHas anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Xetra
Määrä
Osto
0
Myynti
Määrä
0
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Ylin
3,12VWAP
Alin
3,01VaihtoMäärä
0 7 691
VWAP
Ylin
3,12Alin
3,01VaihtoMäärä
0 7 691
Välittäjätilasto
Dataa ei löytynyt